ARS Pharma Slashes 2H Spend by 40%, Aims for Cash Flow Breakeven by End of 2027

summarizeSummary

ARS Pharma reported strong Q2 revenue growth but a widening net loss, and announced a major cost-cutting plan targeting cash flow breakeven by end of 2027.

check_boxKey Events · Earnings and Guidance · SPRY

• Q2 Revenue Doubles, Loss Widens

  Total revenue of $33.7M, up from $15.7M in Q2 2025, driven by $26.2M in U.S. neffy net product revenue. Net loss widened to $62.3M from $44.9M.

• 2H 2026 Expense Cut Over 40%

  Cash-based SG&A and R&D expenses for 2H 2026 expected at $100M-$110M, down from $114M-$126M total including stock-based compensation. This represents a more than 40% reduction in cash-based SG&A from 1H 2026.

• Cash Flow Breakeven by End of 2027

  Management expects the revised cost structure to support a path to cash flow breakeven by the end of 2027, with cash balance of $143.8M as of June 30, 2026.

• New Chief Commercial Officer

  Meg Smith appointed as Chief Commercial Officer effective August 17, 2026, bringing 25+ years of commercial leadership experience, most recently at Dynavax Technologies.

auto_awesomeAnalysis · SPRY · Life Sciences

ARS Pharmaceuticals reported Q2 revenue of $33.7M, more than double the year-ago figure, but a net loss of $62.3M. The company is pivoting from broad consumer advertising to targeted provider engagement, cutting cash-based SG&A by over 40% in 2H 2026. Management expects this to put the company on a path to cash flow breakeven by the end of 2027. The appointment of Meg Smith as Chief Commercial Officer and completion of the field sales expansion support the new strategy. Interim Phase 2b CSU data is expected in Q1 2027, offering a potential expansion opportunity.